|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0031142,
umls-concept:C0045093,
umls-concept:C0069515,
umls-concept:C0205221,
umls-concept:C0242957,
umls-concept:C0279023,
umls-concept:C0599894,
umls-concept:C0728747,
umls-concept:C1292734,
umls-concept:C1512440,
umls-concept:C1522326
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-3-16
|
|
pubmed:abstractText |
Recent studies from this laboratory with (212)Pb-trastuzumab have shown the feasibility of targeted therapy for the treatment of disseminated peritoneal disease using (212)Pb as an in vivo generator of (212)Bi. The objective of the studies presented here was improvement of the efficacy of alpha-particle radioimmunotherapy using a chemotherapeutic agent.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Lead Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Radiation-Sensitizing Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1926-35
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17363549-Animals,
pubmed-meshheading:17363549-Antibodies, Monoclonal,
pubmed-meshheading:17363549-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17363549-Antineoplastic Agents,
pubmed-meshheading:17363549-Carcinoma,
pubmed-meshheading:17363549-Deoxycytidine,
pubmed-meshheading:17363549-Female,
pubmed-meshheading:17363549-Humans,
pubmed-meshheading:17363549-Lead Radioisotopes,
pubmed-meshheading:17363549-Linear Energy Transfer,
pubmed-meshheading:17363549-Mice,
pubmed-meshheading:17363549-Mice, Nude,
pubmed-meshheading:17363549-Peritoneal Neoplasms,
pubmed-meshheading:17363549-Radiation-Sensitizing Agents,
pubmed-meshheading:17363549-Radioimmunotherapy,
pubmed-meshheading:17363549-Receptor, erbB-2,
pubmed-meshheading:17363549-Survival Analysis,
pubmed-meshheading:17363549-Treatment Outcome,
pubmed-meshheading:17363549-Tumor Cells, Cultured,
pubmed-meshheading:17363549-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
|
|
pubmed:affiliation |
Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch and Biometric Research Branch, National Cancer Institute, Bethesda, MD 20892, USA. dm71q@nih.gov
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies,
Research Support, N.I.H., Intramural
|
